BACKGROUND: The success of primary stroke prevention for children with sickle cell disease (SCD) throughout the United States is unknown. Therefore, we aimed to generate national incidence rates of hospitalization for stroke in children with sickle cell disease (SCD) before and after publication of the Stroke Prevention Trial in Sickle Cell Anemia (STOP trial) in 1998. PROCEDURE: We performed a retrospective trend analysis of the 1993-2009 Nationwide Inpatient Sample and Kids' Inpatient Databases. Hospitalizations for SCD patients 0-18 years old with stroke were identified by ICD-9CM code. The primary outcome, the trend in annual incidence rate of hospitalization for stroke in children with SCD, was analyzed by linear regression. Incidence rates of hospitalization for stroke before and after 1998 were compared by the Wilcoxon rank-sum test. RESULTS: From 1993 to 2009, 2,024 hospitalizations were identified for stroke. Using the mean annual incidence rate of hospitalization for stroke from 1993 to 1998 as the baseline, the rate decreased from 1993 to 2009 (point estimate = -0.022/100 patient years [95% CI, -0.039, -0.005], P = 0.027). The mean annual incidence rate of hospitalization stroke decreased by 45% from 0.51 per 100 patient years in 1993-1998 to 0.28 per 100 patient years in 1999-2009 (P = 0.008). Total hospital days and charges attributed to stroke also decreased by 45% and 24%, respectively. CONCLUSIONS: After publication of the STOP trial and hydroxyurea licensure in 1998, the incidence of hospitalization for stroke in children with SCD decreased across the United States, suggesting that primary stroke prevention has been effective nationwide, but opportunity for improvement remains.
BACKGROUND: The success of primary stroke prevention for children with sickle cell disease (SCD) throughout the United States is unknown. Therefore, we aimed to generate national incidence rates of hospitalization for stroke in children with sickle cell disease (SCD) before and after publication of the Stroke Prevention Trial in Sickle Cell Anemia (STOP trial) in 1998. PROCEDURE: We performed a retrospective trend analysis of the 1993-2009 Nationwide Inpatient Sample and Kids' Inpatient Databases. Hospitalizations for SCDpatients 0-18 years old with stroke were identified by ICD-9CM code. The primary outcome, the trend in annual incidence rate of hospitalization for stroke in children with SCD, was analyzed by linear regression. Incidence rates of hospitalization for stroke before and after 1998 were compared by the Wilcoxon rank-sum test. RESULTS: From 1993 to 2009, 2,024 hospitalizations were identified for stroke. Using the mean annual incidence rate of hospitalization for stroke from 1993 to 1998 as the baseline, the rate decreased from 1993 to 2009 (point estimate = -0.022/100 patient years [95% CI, -0.039, -0.005], P = 0.027). The mean annual incidence rate of hospitalization stroke decreased by 45% from 0.51 per 100 patient years in 1993-1998 to 0.28 per 100 patient years in 1999-2009 (P = 0.008). Total hospital days and charges attributed to stroke also decreased by 45% and 24%, respectively. CONCLUSIONS: After publication of the STOP trial and hydroxyurea licensure in 1998, the incidence of hospitalization for stroke in children with SCD decreased across the United States, suggesting that primary stroke prevention has been effective nationwide, but opportunity for improvement remains.
Authors: Lindsay M Bollinger; Kidan G Nire; Melissa M Rhodes; Deena J Chisolm; Sarah H O'Brien Journal: Pediatr Blood Cancer Date: 2010-09-14 Impact factor: 3.167
Authors: C Jason Wang; Patricia L Kavanagh; Alison A Little; Jaime Bruce Holliman; Philippa G Sprinz Journal: Pediatrics Date: 2011-08-15 Impact factor: 7.124
Authors: Jean L Raphael; Priya B Shetty; Hao Liu; Donald H Mahoney; Brigitta U Mueller Journal: Pediatr Blood Cancer Date: 2008-11 Impact factor: 3.167
Authors: Charlotte Baker; Althea M Grant; Mary G George; Scott D Grosse; Thomas V Adamkiewicz Journal: Pediatr Blood Cancer Date: 2015-07-14 Impact factor: 3.167
Authors: Allison A King; John J Strouse; Mark J Rodeghier; Bruce E Compas; James F Casella; Robert C McKinstry; Michael J Noetzel; Charles T Quinn; Rebecca Ichord; Michael M Dowling; J Philip Miller; Michael R Debaun Journal: Am J Hematol Date: 2014-02 Impact factor: 10.047
Authors: Cindy E Neunert; Robert W Gibson; Peter A Lane; Pragya Verma-Bhatnagar; Vaughn Barry; Mei Zhou; Angela Snyder Journal: Am J Prev Med Date: 2016-07 Impact factor: 5.043
Authors: Allison A King; Mark J Rodeghier; Julie Ann Panepinto; John J Strouse; James F Casella; Charles T Quinn; Michael M Dowling; Sharada A Sarnaik; Alexis A Thompson; Gerald M Woods; Caterina P Minniti; Rupa C Redding-Lallinger; Melanie Kirby-Allen; Fenella J Kirkham; Robert McKinstry; Michael J Noetzel; Desiree A White; Janet K Kwiatkowski; Thomas H Howard; Karen A Kalinyak; Baba Inusa; Melissa M Rhodes; Mark E Heiny; Ben Fuh; Jason M Fixler; Mae O Gordon; Michael R DeBaun Journal: Am J Hematol Date: 2014-08-04 Impact factor: 10.047
Authors: Robert J Adams; Dan T Lackland; Lynette Brown; David Brown; Jenifer Voeks; Heather J Fullerton; Julie Kanter; Janet L Kwiatkowski Journal: Am J Hematol Date: 2016-10-25 Impact factor: 10.047
Authors: Jean L Raphael; Suzette O Oyeku; Marc A Kowalkowski; Brigitta U Mueller; Angela M Ellison Journal: Pediatr Blood Cancer Date: 2013-06-18 Impact factor: 3.167